Shares of La Jolla, USA-based biotech Equillium (Nasdaq EQ) were more than 10% lower in Friday’s early trading, following the news that Japan’s Ono Pharmaceutical (TYO: 4528) has opted to allow its option to acquire Equillium’s rights to itolizumab to expire.
The companies entered into an exclusive option and asset purchase agreement in 2022 relating to itolizumab, a first-in-class anti-CD6 monoclonal antibody in development for acute graft-versus-host disease and lupus nephritis, to which Equillium gained rights through an exclusive partnership with India’s Biocon (NSE: BIOCON).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze